Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study

作者：Sean McPhail, Matthew Barclay, Shane A. Johnson, Ruth Swann, Riaz Alvi, Andriana Barisic, Oliver Bucher, Nicola Creighton, Cheryl Denny, Ron Dewar, David Donnelly, Jeff J Dowden, Laura Downie, Norah Finn, Anna Gavin, Steven Habbous, Dyfed Huws, Leon May, Carol McClure, Bjørn Møller, Grace Musto, Yngvar Nilssen, Nathalie Saint‐Jacques, Sabuj Sarker, Lorraine Shack, Xiaoyi Tian, Robert J. S. Thomas, C S Thomson, Haiyan Wang, Ryan Woods, Hui You, Georgios Lyratzopoulos, Alon D. Altman, Damien Bennett, John Butler, David Cameron, Tom Crosby, Llion Davies, Elijah Dixon, Brooke Filsinger, Katharina Förster, Sharon Fung, Elba Gomez Navas, Marianne G. Guren, Jihee Han, Louise Hanna, Samantha Harrison, Mark Lawler, Alana Little, Tom Mala, Neil D. Merrett, David Morrison, Gregg Nelson, Stuart Peacock, David Ransom, Isabelle Ray‐Coquard, Janet L Warlow, Emma Whitfield, John Zalcberg · 发表于：The Lancet Oncology · 年份：2024 · DOI：10.1016/s1470-2045(24)00031-7 · 被引用次数：26 · 研究领域：Esophageal Cancer Research and Treatment、Global Cancer Incidence and Screening、Colorectal Cancer Screening and Detection

BACKGROUND: There are few data on international variation in chemotherapy use, despite it being a key treatment type for some patients with cancer. Here, we aimed to examine the presence and size of such variation. METHODS: This population-based study used data from Norway, the four UK nations (England, Northern Ireland, Scotland, and Wales), eight Canadian provinces (Alberta, British Columbia, Manitoba, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan), and two Australian states (New South Wales and Victoria). Patients aged 15-99 years diagnosed with cancer in eight different sites (oesophageal, stomach, colon, rectal, liver, pancreatic, lung, or ovarian cancer), with no other primary cancer diagnosis occurring from within the 5 years before to 1 year after the index cancer diagnosis or during the study period were included in the study. We examined variation in chemotherapy use from 31 days before to 365 days after diagnosis and time to its initiation, alongside related variation in patient group differences. Information was obtained from cancer registry records linked to clinical or patient management system data or hospital administration data. Random-effects meta-analyses quantified interjurisdictional variation using 95% prediction intervals (95% PIs). FINDINGS: Between Jan 1, 2012, and Dec 31, 2017, of 893 461 patients with a new diagnosis of one of the studied cancers, 111 569 (12·5%) did not meet the inclusion criteria, and 781 ...